Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are ...

Eli Lilly’s request to intervene in a suit filed by compounding pharmacies against the FDA reflects a belief the outcome ...

Roche has once again returned to China to bolster its antibody-drug conjugate pipeline, this time striking a licensing deal ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Regulators squeezed in two final approvals before the calendar change with the UK approval of Merck’s Winrevair and the FDA’s ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...

Job postings in California took a dip in December during the holiday period, but activity is expected to pick up in January.

As market values increase for computational biology and data science, biopharma companies are looking to hire R&D ...

High profile failures and long timeframes for revenue have shifted investment away from Phase I, as VCs seek to mitigate risk ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

The mega-blockbuster weight loss GLP-1 drug is now also approved to treat obstructive sleep apnea in adults with obesity, in ...